Skip Navigation


European Heart Journal Advance Access originally published online on May 12, 2006
European Heart Journal 2006 27(12):1505; doi:10.1093/eurheartj/ehi887
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/12/1505    most recent
ehi887v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Serebruany, V. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serebruany, V. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Dyspnoea after AZD6140: safety first?

Victor L. Serebruany

Johns Hopkins University
Towson
MD 21204
USA
E-mail address: heartdrug@aol.com

The first 10% of the full text of this article appears below.

Husted et al.1 published dose-finding Phase 2 randomized study comparing novel oral reversible platelet P2Y12 antagonist, AZD6140, with conventional clopidogrel on top of low-dose aspirin. The authors should be acknowledged for the thoughtful design, detailed analysis, well-balanced opinions, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?